Use the hyperlinks, where available to access additional clinical trial information.
A Phase I, Open Label, Multi-Center, Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 in Patients With Advanced Solid Tumors or B-cell Lymphoma
Curon Biopharmaceutical (Australia) Co Pty Ltd
Eligible patients will receive CN1 by intravenous infusion on Day 1 of each cycle each 3 week cycle. The 5 planned dose levels are 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg.